Ishida Susumu, Usui Tomohiko, Yamashiro Kenji, Kaji Yuichi, Ahmed Ednan, Carrasquillo Karen G, Amano Shiro, Hida Tetsuo, Oguchi Yoshihisa, Adamis Anthony P
Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA.
Invest Ophthalmol Vis Sci. 2003 May;44(5):2155-62. doi: 10.1167/iovs.02-0807.
The objectives of this study were to characterize the differential potency of two major VEGF isoforms, VEGF(120) and VEGF(164), for inducing leukocyte stasis (leukostasis) within the retinal vasculature and blood-retinal barrier (BRB) breakdown and to determine whether endogenous VEGF(164) mediates retinal leukostasis and BRB breakdown in early and established diabetes.
Retinal leukostasis and BRB breakdown were simultaneously quantified by combining concanavalin A lectin (ConA) perfusion labeling with a fluorophotometric dextran leakage assay. CD45 immunohistochemistry was performed to confirm that ConA-stained cells within the vasculature were leukocytes. Retinal leukostasis and BRB breakdown were compared in nondiabetic rats receiving intravitreous injections of VEGF(120) or VEGF(164). Retinal intercellular adhesion molecule (ICAM)-1 and VEGF protein levels were studied by Western blot and ELISA, respectively. An anti-VEGF(164(165)) aptamer (EYE001) was administered by intravitreous injection to 2-week and 3-month diabetic rats, and the effect on retinal leukostasis and BRB breakdown was quantified.
Compared with VEGF(120), VEGF(164) more potently increased retinal ICAM-1 levels (2.2-fold), leukostasis (1.9-fold), and BRB breakdown (2.1-fold, P < 0.01 for all), despite negligible differences in vitreoretinal VEGF levels at the time of evaluation (P > 0.05). Retinal leukostasis and leakage increased with the duration of diabetes (P < 0.01) and correlated closely (P < 0.01, r = 0.889). The isoform-specific blockade of endogenous VEGF(164) with EYE001 resulted in a significant suppression of retinal leukostasis and BRB breakdown in both early (72.4% and 82.6%, respectively) and established (48.5% and 55.0%, respectively) diabetes (P < 0.01).
On an equimolar basis, VEGF(164) is at least twice as potent as VEGF(120) at inducing ICAM-1-mediated retinal leukostasis and BRB breakdown in vivo. The inhibition of diabetic retinal leukostasis and BRB breakdown with EYE001 in early and established diabetes indicates that VEGF(164) is an important isoform in the pathogenesis of early diabetic retinopathy.
本研究的目的是表征两种主要的血管内皮生长因子(VEGF)异构体VEGF(120)和VEGF(164)在诱导视网膜血管内白细胞停滞(白细胞淤滞)和血视网膜屏障(BRB)破坏方面的差异效力,并确定内源性VEGF(164)是否在早期和已确诊的糖尿病中介导视网膜白细胞淤滞和BRB破坏。
通过将伴刀豆球蛋白A凝集素(ConA)灌注标记与荧光光度法葡聚糖渗漏试验相结合,同时对视网膜白细胞淤滞和BRB破坏进行定量。进行CD45免疫组织化学以确认血管内ConA染色的细胞是白细胞。比较接受玻璃体内注射VEGF(120)或VEGF(164)的非糖尿病大鼠的视网膜白细胞淤滞和BRB破坏情况。分别通过蛋白质印迹法和酶联免疫吸附测定法研究视网膜细胞间黏附分子(ICAM)-1和VEGF蛋白水平。将抗VEGF(164(165))适体(EYE001)通过玻璃体内注射给予2周和3个月龄的糖尿病大鼠,并对其对视网膜白细胞淤滞和BRB破坏的影响进行定量。
与VEGF(120)相比,VEGF(164)更有效地提高了视网膜ICAM-1水平(2.2倍)、白细胞淤滞(1.9倍)和BRB破坏(2.1倍,所有P<0.01),尽管在评估时玻璃体内视网膜VEGF水平差异可忽略不计(P>0.05)。视网膜白细胞淤滞和渗漏随糖尿病病程增加(P<0.01),且密切相关(P<0.01,r=0.889)。用EYE001对内源性VEGF(164)进行异构体特异性阻断,导致早期(分别为72.4%和82.6%)和已确诊(分别为48.5%和55.0%)糖尿病的视网膜白细胞淤滞和BRB破坏均得到显著抑制(P<0.01)。
在等摩尔基础上,VEGF(164)在体内诱导ICAM-1介导的视网膜白细胞淤滞和BRB破坏方面的效力至少是VEGF(120)的两倍。EYE001在早期和已确诊的糖尿病中对糖尿病性视网膜白细胞淤滞和BRB破坏的抑制作用表明,VEGF(164)是早期糖尿病性视网膜病变发病机制中的一种重要异构体。